Lee's Pharmaceutical Holdings Ltd. announced the signing of a license and supply agreement with GP Pharm, S.A., Spain for obtaining the Technological transfer for the registration, production, distribution and marketing of Leuprolide, throughout China, Hong Kong and Macau. Under the terms of agreement, GP Pharm agrees to manufacture for Lee's the finished product ready for administration (1 month formulation-3.75 mg and 3 month depot); and/or supplies the bulk product containing Leuprolide acetate (in the form of microcapsules) for the preparation of finished products. Leuprolide acetate, belongs to a group of drugs called agonists of luteinising hormone-releasing hormone, which are drugs that reduce testosterone (sex hormone).

Leuprolide acetate is a hormonal androgen deprivation therapy to prevent tumor growth in patients with advanced prostate cancer. Leuprolide 1 month is the first controlled-release drug system entirely developed by GP Pharm and indicated for the treatment of advance prostate cancer. It has been approved in 23 countries in the European Union, including Spain, Germany, the UK and Italy, etc.

It is expected to be filed in the USA shortly and in a number of other countries worldwide. Other presentations of Leuprolide are currently under development by GP Pharm, mainly within the framework of therapeutic areas for oncology (prostate cancer, ovarian cancer, breast cancer, carcinoid syndrome), central nervous system and cardiovascular diseases.